## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.7% below STRENGTH zone (4.0-10.0%); PEG 3.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($543.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Intuitive Surgical (ISRG) Declined Due to Managementâ€™s Cautious Commentary**
- Source: Yahoo! Finance Canada | 20251203T135200 | Somewhat-Bearish | Relevance: 100%
- Intuitive Surgical (ISRG) stock declined despite strong second-quarter results and raised full-year procedure guidance. The decline is attributed to management's cautious commentary on the European capital expenditure environment and conservative forward margin guidance, impacting investor sentiment. Brown Advisory's Large-Cap Growth Strategy noted this in its Q3 2025 investor letter, while also mentioning the strategic choice to underweight highly speculative AI stocks.

**2. OMERS ADMINISTRATION Corp Has $7.95 Million Holdings in Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251202T020926 | Somewhat-Bullish | Relevance: 100%
- OMERS ADMINISTRATION Corp decreased its stake in Intuitive Surgical, Inc. to 14,637 shares valued at $7.95 million after selling 5,368 shares in Q2. Despite this, Intuitive Surgical outperformed quarterly expectations with $2.40 EPS and $2.51 billion in revenue, reflecting a 22.9% year-over-year increase. However, recent insider selling, including EVP Henry L. Charlton's sale of 13,731 shares for $7.96 million, indicates a total of $48.0 million in insider sales over the last three months.

**3. Chmn Guthart Files To Sell 22,806 Of Intuitive Surgical Inc [ISRG]**
- Source: TradingView | 20251202T020821 | Somewhat-Bearish | Relevance: 100%
- Gary S. Guthart, Chairman of the Board of Intuitive Surgical Inc [ISRG], filed a Form 144 on December 1, 2025, proposing to sell 22,806 restricted shares. The sale is planned for approximately December 1, 2025, through Morgan Stanley Smith Barney LLC, pursuant to a prearranged trading plan (10b5-1). This filing allows the sale of restricted shares within 90 days of submission to the SEC.

**4. Building a better robot: How Virtual Incision plans to challenge Intuitive**
- Source: MedTech Dive | 20251201T145123 | Neutral | Relevance: 100%
- Virtual Incision is positioning its miniaturized M2 robot to compete with Intuitive Surgical's dominance in robotic surgery. Led by CEO Jim Alecxih, the company aims to differentiate itself by designing compact, single-port systems that are easier to use and store, thereby expanding access to minimally invasive procedures. Virtual Incision plans to pursue clearances for various applications beyond colectomy, including gynecology and hernia repair.

**5. Intuitive Surgical (ISRG) Stock Forecast for December 1, 2025: Price, News and Analysis Before the Bell**
- Source: ts2.tech | 20251201T105120 | Bullish | Relevance: 100%
- This article provides a comprehensive forecast for Intuitive Surgical (ISRG) stock as of December 1, 2025, detailing its recent price performance, institutional activity, and AI-driven research coverage. It highlights ISRG's strong Q3 2025 earnings, its position near 52-week highs, and the nuanced institutional buying and selling patterns. The analysis concludes that while ISRG is a high-quality growth stock with excellent fundamentals, its premium valuation suggests limited short-term upside unless growth significantly outpaces expectations.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.2% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.5M in recent transactions.
3. Valuation stretched: PEG 3.5x requires aggressive growth execution.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.55 signals overvaluation risk, limited margin of safety. Forward P/E 58.4x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $207.1B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.55 |
| Forward P/E | 58.4 |
| Current P/E | 65.9 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 2.5% to -0.7% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-2.61), momentum weakening. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.73% (CS: 44) | Neutral |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | -2.61 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.116x | Above |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $569.71
- **Stop Loss:** $543.65 (4.6% risk)
- **Target:** $595.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 36
- **Position Value:** $20,509.56
- **Portfolio %:** 20.51%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*